Study of DefenCath for Catheter-Related Infections in Children
This study is looking at the safety of a catheter lock solution called (taurolidine and heparin) in children from birth up to 17 years old who are on long-term kidney dialysis. The main goal is to see how long it takes for children using this solution to develop a catheter-related bloodstream infection (CRBSI) compared to those receiving standard care. Researchers will also track any side effects or serious problems. This study is required after the solution has already been approved for use. We are looking to enroll 36 participants.
- Study design
- This is an open-label study, meaning both you and your doctors will know which treatment you are receiving. It aims to enroll 36 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 13 months to track the time to their first catheter-related bloodstream infection and any side effects.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06714864
Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age
Recruiting
PHASE4Up to 17InterventionalPreventionCorMedix Therapeutics
~36 participants
Updated 2026-08-05 on ClinicalTrials.gov
What's tested:(taurolidine and heparin) catheter lock solutionStandard of Care
At a glance
Recruiting sites
6 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to first clinical diagnosis of Catheter-related Bloodstream Infections (CRBSI)
Measured over Patient has been randomized and has received at least 1 instillation of the assigned lock solution, and has received confirmed diagnosis of CRBSI (up to 13 months)
+1 more outcome measured
Conditions
Where it's being run
6 sites across 6 statesAlabama1
Arizona1
California1
Delaware1
New Jersey1
Texas1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
The investigator, or a person designated by the investigator, will obtain written informed consent from each study participant's legal guardian and the participant's assent, when applicable, before any study-specific activity is performed. All legal guardians should be fully informed, and participants should be informed to the fullest extent possible, about the study in language and terms they are able to understand.
A legal guardian or primary caregiver must be available to help the study-site personnel ensure follow up; accompany the participant to the study site on each assessment day according to the schedule of activities (SoA) (e.g., able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures); consistently and consecutively be available to provide information on the participant during the scheduled study visits; accurately and reliably dispense study intervention as directed.
The participant has kidney failure and undergoes chronic hemodialysis (HD) at least 2 times per week.
The participant has an HD central venous catheter (CVC) and is placed in a jugular or subclavian vein.
The participant has demonstrated the ability to achieve an appropriate minimum blood flow (Qb) for the participant's relative age and weight for at least 2 consecutive dialysis sessions to enable successful HD.
The participant is likely to require the use of a CVC for at least 60 days, based on clinical assessment.
The participant is willing to comply with specified follow-up evaluations and prescribed dialysis therapy.
The participant is not expected to expire within 180 days, based on clinical assessment.
Female participants of childbearing potential:
Must agree to abide by contraception requirements, must not be lactating, and avoid pregnancy during study participation from the first Screening visit until 30 days after the last administration of study treatment.
Must commit to an additional method of birth control in addition to male partners agreeing to use condoms with spermicide, throughout the study including for at least 30 days after the last administration of study treatment:
True abstinence: Refraining from heterosexual intercourse when this is in line with the preferred and usual lifestyle of the participant (periodic abstinence \[e.g., calendar, ovulation, symptothermal, post ovulation methods\] and withdrawal are not acceptable).
Progestogen only hormonal birth control (oral, injectable, or implantable) associated with inhibition of ovulation initiated at least 30 days before study dose administration.
Bilateral tubal occlusion/ligation.
Intrauterine device.
Intrauterine hormone releasing system.
Vasectomized partner.
NOTE: If the childbearing potential changes after start of the study (e.g., a premenarchal female participant experiences menarche) or the risk of pregnancy changes (e.g., a female participant who is not heterosexually active becomes active), the participant must discuss this with the investigator, who should determine if a female participant must begin a highly effective method of contraception, or a male participant must use a condom. If reproductive status is questionable, additional evaluation should be considered.
Male participants who are sexually active with a female partner of childbearing potential must agree to use male condoms and spermicide, even if the male participant has undergone a successful vasectomy (males with vasectomy can use condoms without spermicide), from Day 1 until at least 30 days after the last administration of study treatment.
Exclusion
Any participant who is currently receiving systemic antibiotics. Topical antibiotic use is permitted.
Visible evidence of compromised skin integrity is present at the catheter exit site or evidence of a catheter exit site infection.
The participant has received any thrombolytic treatment (i.e., tissue plasminogen activator \[tPA\] - Cathflo®), not as part of the institution's standard of care for patency management, in their current catheter within 30 days of randomization.
The fill volume of catheter lumen(s) is unknown or cannot be determined.
The participant uses any type of antimicrobial-coated or heparin-coated catheter.
Documented chronic bleeding diathesis, active or recurrent bleeding within 30 days prior to randomization.
Documented history of an atrial thrombus or known hypercoagulable state.
The participant has open, non-healing skin ulcers.
Any participant who has received an allogeneic hematopoietic stem cell transplant within the last year.
The participant has current requirement for systemic chemotherapy and/or immunosuppression and absolute neutrophil count \<500 cells/µL that occurred in the past 4 weeks.
An active malignancy that either in and of itself or by virtue of its treatment with chemotherapy or biologic therapy results in neutropenia, leukopenia and/or immunosuppression.
Known allergy or absolute contraindication to taurolidine, citrate, or heparin, or a history of heparin induced thrombocytopenia (HIT).
Unstable malignancy.
Cirrhosis with encephalopathy.
The participant is currently taking another medication with known systemic drug interaction with taurolidine, citrate, or heparin.
The participant is anticipated to receive a renal transplant within 90 days (participants can be on the transplant list, but a participant with a known or anticipated transplant date within the next 90 days should be excluded).
The participant has a clinically significant cardiac rhythm or functional disorder.
The participant has severe hypoxemia, respiratory acidosis, asphyxia, or hypotension prior to randomization based on assessment of the investigator.
Any other medical condition which renders the participant unable to or unlikely to complete the study, or which would interfere with optimal participation in the study or produce significant risk to the participant.
What this trial measures
- Time to first clinical diagnosis of Catheter-related Bloodstream Infections (CRBSI)Patient has been randomized and has received at least 1 instillation of the assigned lock solution, and has received confirmed diagnosis of CRBSI (up to 13 months)
To demonstrate the effectiveness of DefenCath as a catheter lock solution (CLS) for prevention of CRBSI in pediatric participants receiving chronic hemodialysis (HD) through a central venous catheter (CVC) for the treatment of kidney failure.
- Descriptive analysis characterizing the relative rates of deaths, AEs, and SAEsPatient has been randomized and has received at least 1 instillation of the assigned lock solution, and has received confirmed diagnosis of CRBSI (up to 13 months)
To demonstrate safety of DefenCath as a CLS in pediatric participants receiving chronic HD through a CVC for the treatment of kidney failure